Navidea Biopharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
May 29 2014 - 7:30AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a
biopharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that Thomas Tulip, President
and Chief Business Officer, will participate at the Jefferies 2014
Global Healthcare Conference June 2-5, 2014 at the Grand Hyatt in
New York City, NY. Dr. Tulip will present a Company update on
Thursday, June 5, 2014 at 1:30 PM EDT.
Investors and the public are invited to listen to a live webcast
of Dr. Tulip’s presentation at http://wsw.com/webcast/jeff82/NAVB.
Following the conference, the webcast will be archived for
approximately 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. Navidea is developing multiple precision diagnostic
products and platforms, including NAV4694, NAV5001, Manocept™ and
NAV1800 (RIGScan™), to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making and, ultimately, patient care. Lymphoseek®
(technetium 99m tilmanocept) Injection, Navidea’s first commercial
product from the Manocept platform, was approved by the FDA in
March 2013. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company’s pipeline through selective
acquisitions, global partnering and commercialization efforts. For
more information, please visit www.navidea.com.
Navidea BiopharmaceuticalsBrent Larson, 614-822-2330Executive VP
& CFOorSharon Correia, 978-655-2686Associate Director,
Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024